In a report released today, Charles Duncan from Cantor Fitzgerald maintained a Buy rating on Intra-Cellular Therapies (ITCI), with a price target of $32. The company’s shares closed yesterday at $15.34, close to its 52-week low of $13.29.
Duncan observed:
“Core to our investment thesis is the complete NDA filing for lumateperone in schizophrenia, which we believe has a high probability of approval based on two large studies that met their primary endpoints and a positive pre-NDA meeting with FDA. In addition, Luma’s differentiated pharmacology results in tolerability and a benign safety profile unlike other approved APs.”
According to TipRanks.com, Duncan is a 1-star analyst with an average return of -1.2% and a 42.0% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
Intra-Cellular Therapies has an analyst consensus of Strong Buy, with a price target consensus of $27.75.
See today’s analyst top recommended stocks >>
Based on Intra-Cellular Therapies’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $41.52 million. In comparison, last year the company had a GAAP net loss of $22.87 million.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is neutral on the stock. Most recently, in October 2018, Richard A. Lerner, a Director at ITCI bought 12,500 shares for a total of $18,750.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, I
